Brief: Sab Biotherapeutics Granted U.S. FDA's 'Fast Track' tag for influenza therapy

SAB Biotherapeutics

13/04/2023 14:15

April 13 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS GRANTED FAST TRACK DESIGNATION FROM
FDA FOR
SAB-176 INFLUENZA IMMUNOTHERAPY WITH HIGH CROSS-REACTIVITY TO
MULTIPLE STRAINS OF INFLUENZA
    * SAB BIOTHERAPEUTICS GRANTED FAST TRACK DESIGNATION FROM
FDA FOR
SAB-176 INFLUENZA IMMUNOTHERAPY WITH HIGH CROSS-REACTIVITY TO
MULTIPLE STRAINS OF INFLUENZA
    * SAB BIOTHERAPEUTICS INC - FDA GREENLIGHTS ADVANCEMENT OF
SAB-176
PHASE 2B TRIAL AND MANUFACTURING APPROACH TO ADDRESS INFLUENZA
STRAIN CHANGE
    * SAB BIOTHERAPEUTICS - GOT FDA GUIDANCE, REGULATORY
ALIGNMENT ON
ADVANCING SAB-176 IN NEXT PHASE OF DEVELOPMENT, INCLUDING PHASE
2B TRIAL STUDY DESIGN
    * SAB BIOTHERAPEUTICS INC - STUDY WILL EVALUATE SAFETY AND
EFFICACY OF SAB-176 IN HIGH-RISK PATIENTS WITH TYPE A OR TYPE B
INFLUENZA ILLNESS

Source text for Eikon:  ID:nGNX5F5d9L 
Further company coverage:  SABS.O 

 ((Reuters.Briefs@thomsonreuters.com;))